Kett M M, Alcorn D, Bertram J F, Anderson W P
Department of Anatomy and Cell Biology, University of Melbourne, Parkville, Victoria, Australia.
J Hypertens. 1996 Jan;14(1):107-13.
A reduction in glomerular number and/or size has been implicated in the development of hypertension. This study investigated whether differences in glomerular number and/or size occur during the development of hypertension in the spontaneously hypertensive rat (SHR) and whether angiotensin II is responsible for any glomerular differences.
SHR (n=6) and Wistar-Kyoto (WKY) rats (n=6) were administered the angiotensin II type I receptor antagonist TCV-116 from 4 to 10 weeks of age. At 10 weeks of age, the kidneys from these rats and those from untreated SHR (n=6) and WKY rats (n=6) controls were perfusion fixed at physiological pressures and analysed using unbiased stereological techniques.
There were no significant differences in glomerular number, glomerular volume or total glomerular volume between SHR and WKY rats. Treatment of SHR with TCV-116 significantly lowered systolic blood pressure but had no significant effect on glomerular number or volume or total glomerular volume. Treatment of WKY rats with TCV-116 reduced systolic blood pressure, body weight, glomerular volume and total glomerular volume; however, total glomerular volume per body weight of treated WKY rats was not significantly different from that of untreated WKY rats.
There were no differences in glomerular number or volume in SHR compared with WKY rats at 10 weeks of age. We therefore conclude that glomerular changes are not responsible for the development of hypertension in SHR. Angiotensin II, via the type 1 receptor, does not contribute to glomerular growth during the development of hypertension in the SHR.
肾小球数量和/或大小的减少与高血压的发生有关。本研究调查了自发性高血压大鼠(SHR)高血压发展过程中肾小球数量和/或大小是否存在差异,以及血管紧张素II是否与任何肾小球差异有关。
从4至10周龄开始,给SHR(n = 6)和Wistar-Kyoto(WKY)大鼠(n = 6)施用血管紧张素II 1型受体拮抗剂TCV-116。在10周龄时,对这些大鼠以及未治疗的SHR(n = 6)和WKY大鼠(n = 6)对照组的肾脏在生理压力下进行灌注固定,并使用无偏倚的体视学技术进行分析。
SHR和WKY大鼠之间在肾小球数量、肾小球体积或总肾小球体积方面没有显著差异。用TCV-116治疗SHR可显著降低收缩压,但对肾小球数量、体积或总肾小球体积没有显著影响。用TCV-116治疗WKY大鼠可降低收缩压、体重、肾小球体积和总肾小球体积;然而,治疗后的WKY大鼠每体重的总肾小球体积与未治疗的WKY大鼠没有显著差异。
10周龄时,与WKY大鼠相比,SHR的肾小球数量或体积没有差异。因此,我们得出结论,肾小球变化不是SHR高血压发生的原因。在SHR高血压发展过程中,血管紧张素II通过1型受体对肾小球生长没有作用。